Skip to main content
SpringerLink
Log in

Lymphoma: Management Using PET/CT

  • Chapter
Book cover Diseases of the Abdomen and Pelvis 2014–2017

  • 1086 Accesses

Abstract

[18F]-fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography (PET/CT) is considered the standard imaging modality in Hodgkin’s disease and aggressive non-Hodgkin’s lymphoma. In the European Society of Medical Oncology guidelines, FDGPET/CT is strongly recommended for staging and restaging Hodgkin’s disease and diffuse large B-cell lymphoma

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hutchings M, Loft A, Hansen M et al (2006) Positron emission tomography with or without computed tomography in the primary staging of Hodgkin’s lymphoma. Haematologica 91:482–489.

    PubMed  Google Scholar 

  2. Pelosi E, Pregno P, Penna D et al (2008) Role of whole body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non-Hodgkin lymphoma. Radiol Med 113:578–590.

    Article  CAS  PubMed  Google Scholar 

  3. Bangerter M, Moog F, Buchmann I et al (1998) Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin’s disease. Ann Oncol 9:1117–1122.

    Article  CAS  PubMed  Google Scholar 

  4. Rigacci L, Vitolo U, Nassi L et al (2007) Positron emission tomography in the staging of patients with Hodgkin’s lymphoma: a prospective multicentric study by the Intergruppo Italiano Linfomi. Ann Hematol 86:897–903.

    Article  PubMed  Google Scholar 

  5. Shipp MA, Harrington DP, Anderson JR et al (1993) Development of a predictive model for aggressive lymphoma: The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med 329:987–994.

    Article  Google Scholar 

  6. Hasenclever D, Diehl V (1998) A prognostic score for advanced Hodgkin’s disease: International Prognostic Factors Project on advanced Hodgkin’s disease. N Engl J Med 339:1506–1514.

    Article  CAS  PubMed  Google Scholar 

  7. Spaepen K, Stroobants S, Dupont P et al (2002) Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma. Ann Oncol 13:1356–1363.

    Article  CAS  PubMed  Google Scholar 

  8. Haioun C, Itti E, Rahmouni A et al (2005) [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 106:1376–1381.

    Article  CAS  PubMed  Google Scholar 

  9. Mikhaeel NG, Hutchings M, Fields PA et al (2005) FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in highgrade non-Hodgkin lymphoma. Ann Oncol 16:1514–1523.

    Article  CAS  PubMed  Google Scholar 

  10. Safar V, Dupuis J, Jardin F et al (2009) Early 18 fluourodeoxyglucose PET scan as a prognostic tool in diffuse large B-cell lymphoma patients treated with an anthracycline-based chemotherapy plus rituximab. Blood 114:45.

    Google Scholar 

  11. Cashen A, Dehdashti F, Luo J et al (2008) Poor predictive value of FDG-PET/CT performed after 2 cycles of R-CHOP in patients with diffuse large B-cell lymphoma (DLCL). Blood 112:144.

    Google Scholar 

  12. Gallamini A, Hutchings M, Rigacci L et al (2007) Early interim 2-[18F]fluoro-2-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 25:3746–3752.

    Article  CAS  PubMed  Google Scholar 

  13. Cerci JJ, Pracchia LF, Linardi CCG et al (2010) 18F-FDG PET after 2 cycles of ABVD predicts eventfree survival in early and advanced Hodgkin lymphoma. J Nucl Med 51:1337–1343.

    Article  CAS  PubMed  Google Scholar 

  14. Spaepen K, Stroobants S, Dupont P et al (2001) Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin’s lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 19:414–419.

    CAS  PubMed  Google Scholar 

  15. Engert A, Kobe C, Markova J et al (2010) Assessment of residual bulky tumor using FDG-PET in patients with advanced-stage Hodgkin lymphoma after completion of chemotherapy: final report of the GHSG HD15 trial. Blood 116:336.

    Google Scholar 

  16. Cerci JJ, Trindade E, Pracchia LF et al (2010) Cost effectiveness of positron emission tomography in patients with Hodgkin’s lymphoma in unconfirmed complete remission or partial remission after firstline therapy. J Clin Oncol 28:1415–1421.

    Article  PubMed  Google Scholar 

  17. Zinzani PL, Stefoni V, Tani M et al (2009) The role of FDGPET scan in the follow-up of lymphoma: experience on 421 patients. J Clin Oncol 27:1781–1787.

    Article  PubMed  Google Scholar 

  18. Petrausch U, Samaras P, Haile SR et al (2010) Risk-adapted FDG-PET/CT-based follow-up in patients with diffuse large Bcell lymphoma after firstline therapy. Ann Oncol 21:1694–1698.

    Article  CAS  PubMed  Google Scholar 

  19. Petrausch U, Samaras P, Veit-Haibach P et al (2010) Hodgkin’s lymphoma in remission afer first-line therapy: which patients need FDG-PET/CT for follow-up? Ann Oncol 21:1053–1057.

    Article  CAS  PubMed  Google Scholar 

  20. Spaepen K, Stroobants S, Dupont P et al (2003) Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood 102:53–59.

    Article  CAS  PubMed  Google Scholar 

  21. Lambert JR, Bomanji JB, Peggs KS et al (2010) Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma. Blood 115:2763–2768.

    Article  CAS  PubMed  Google Scholar 

  22. Lin C, Itti E, Haioun C et al (2007) Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med 48:1626–1632.

    Article  PubMed  Google Scholar 

  23. Cheson BD, Horning SJ, Coiffier B et al (1999) Report of an International Workshop to standardize response criteria for non-Hodgkin’s lymphomas. J Clin Oncol 17:1244–1253.

    CAS  PubMed  Google Scholar 

  24. Cheson BD, Pfistner B, Juweid ME et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579–586.

    Article  PubMed  Google Scholar 

  25. Dupuis J, Itti E, Rahmouni A et al (2009) Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria. Ann Oncol 20:503–507.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Oncology & Nuclear Medicine, Zurich, Switzerland

    Niklaus G. Schaefer

Authors
  1. Niklaus G. Schaefer
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Radiology, University Hospital, Zurich, Switzerland

    J. Hodler

  2. Nuclear Medicine, University Hospital, Zurich, Switzerland

    G. K. von Schulthess

  3. Radiology, Kantonsspital, Baden, Switzerland

    R. A. Kubik-Huch

  4. Kilchberg/Zurich, Switzerland

    Ch. L. Zollikofer

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Italia

About this chapter

Cite this chapter

Schaefer, N.G. (2014). Lymphoma: Management Using PET/CT. In: Hodler, J., von Schulthess, G.K., Kubik-Huch, R.A., Zollikofer, C.L. (eds) Diseases of the Abdomen and Pelvis 2014–2017. Springer, Milano. https://doi.org/10.1007/978-88-470-5659-6_34

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-5659-6_34

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-5658-9

  • Online ISBN: 978-88-470-5659-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation